Grossman - Figure 12
Final primary results from BA06 30894
FIG. 12: This Figure shows the final primary results from BA06 30894.[4] Overall survival (upper left), metastasis-free survival (upper right), locoregional disease-free survival (lower left), and disease-free survival (lower right) were all improved in patients receiving neoadjuvant chemotherapy compared with patients who did not receive neoadjuvant chemotherapy. All the differences were statistically significant except for locoregional disease-free survival, which approached statistical significance.
References
International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group; Griffiths G, Hall R, Sylvester R, et al. International Phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171−7 https://doi.org/10.1200/JCO.2010.32.3139
